Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM) Meeting Abstract
| Authors: | Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Rocafiguera, A. O.; Nooka, A. K.; Rosiñol, L.; Bahlis, N. J.; RodrÃguez-Otero, P.; Martin, T. G.; Diels, J.; Van Sanden, S.; Pei, L.; Ammann, E.; Kobos, R.; Slavcev, M.; Smit, J.; Londhe, A.; Krishnan, A. Y. |
| Abstract Title: | Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302073 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.8035 |
| Notes: | Meeting Abstract: 8035 -- Meeting also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work